Publication: New study on Hyglos PRF-119, a novel antimicrobial against Staphylococcus aureus

In the 2011 September issue of Antimicrobial Agents and Chemotherapy, Vol. 55, No. 9

In vitro Activity against Staphylococcus aureus of a Novel Antimicrobial Agent, PRF-119, a Recombinant Chimeric Bacteriophage Endolysin

Evgeny A. Idelevich, Christof von Eiff, Alexander W. Friedrich, Domenico Iannelli, Guiqing Xia, Georg Peters, Andreas Peschel, Ingrid Wanninger and Karsten Becker

Abstract:

Antistaphylococcal activity of the novel chimeric endolysin PRF-119 was evaluated with the microdilution method. The MIC₅₀ and MIC₉₀ of 398 methicillin-susceptible Staphylococcus aureus isolates were 0.098 µg/ml and 0.391 µg/ml, respectively (range, 0.024 to 0.780 µg/ml). Both the MIC₅₀ and MIC₉₀ values of 776 methicillin-resistant S. aureus isolates were 0.391 µg/ml (range, 0.024 to 1.563 µg/ml). All 192 clinical isolates of coagulase-negative staphylococci exhibited MIC values of >50 µg/ml. In conclusion, PRF-119 exhibited very good activity specifically against S. aureus.

Obtain the complete paper here